North America Next-Generation Sequencing Market (2025-2035)
The North America Next-Generation Sequencing (NGS) market is experiencing rapid advancement driven by technological innovations and expanding applications across healthcare and life sciences. This market encompasses a range of sequencing technologies, including whole genome, whole exome, targeted sequencing, and more, accessible via diverse channels. The sector is witnessing increased adoption for personalized medicine, clinical diagnostics, and research, making it crucial in modern healthcare infrastructure.
Latest Market Dynamics
Key Drivers
- Rising demand for personalized medicine: Precision healthcare initiatives are propelling NGS utilization as clinicians rely on comprehensive genomic data for informed treatment. In 2024, Illumina launched new clinical solutions making NGS more accessible for oncology and rare disease diagnostics.
- Declining sequencing costs and faster turnaround times: Technological breakthroughs have reduced sequencing costs substantially while improving data accuracy. Pacific Biosciences' recent partnerships with academic centers have enabled larger population sequencing projects at lower costs.
Key Trends
- Integration of AI and bioinformatics: Advanced analytics and AI are increasingly merged with NGS platforms to accelerate data interpretation. Thermo Fisher Scientific’s Ion Torrent platform now offers integrated analytics powered by machine learning.
- Expansion of liquid biopsy applications: NGS is being adopted for noninvasive cancer diagnostics through liquid biopsies. Guardant Health's North American launch of expanded liquid biopsy panels in 2024 demonstrates this trend.
Key Opportunities
- Growing clinical adoption in oncology: Increased clinical evidence supports NGS-guided cancer therapy selection. Roche’s recent partnership with US healthcare networks to provide comprehensive genomic profiling panels exemplifies this opportunity.
- Agricultural genomics: NGS is being leveraged to enhance crop and livestock traits. In 2024, Agilent Technologies collaborated with agrigenomics firms to develop and validate high-throughput sequencing assays for North American agriculture.
Key Challenges
- Data management, storage, and analysis: The massive data output from NGS requires robust, scalable, and interoperable data infrastructure. QIAGEN faces ongoing challenges in streamlining end-to-end genomic data workflows for clients.
- Regulatory and reimbursement complexities: Changing regulatory landscapes and slow reimbursement pathways impede the integration of NGS into clinical care. Oxford Nanopore continues to navigate these hurdles as it expands clinical diagnostics offerings in North America.
Key Restraints
- High initial investment and operational costs: While costs per genome have fallen, total outlay for NGS infrastructure remains significant. Genapsys has delayed potential market expansion due to capital constraints.
- Limited skilled workforce: Demand for bioinformatics professionals outpaces supply, slowing the adoption rate. Bio-Rad Laboratories has invested in workforce development initiatives, but talent shortage persists.
North America NGS Market Share by Type, 2025
By type, Whole Genome Sequencing dominates the North America NGS market, driven by widespread research and precision medicine needs. Whole Exome and Targeted Sequencing segments follow, serving applications in diagnostics and specific gene panels. Technological innovations continue to broaden the accessibility and utility of RNA and Methylation sequencing.
North America NGS Market Share by Application, 2025
Diagnostics take the leading share of the NGS application market in North America, underscoring the transition of sequencing technologies from research to clinical environments. Drug discovery and biomarker discovery remain substantial, followed by mounting implementation in personalized medicine. Agricultural and animal research, while smaller, is growing as adoption broadens.
North America NGS Market Revenue (USD Million), 2020-2035
From 2020 to 2035, the North America NGS market is projected to rise significantly. Revenue is anticipated to grow from 3,300 million USD in 2020 to 11,900 million USD by 2035, reflecting rapid adoption in clinical diagnostics, expanding applications, and supportive regulatory environments. This growth is seen across all major segments, with particularly robust increases in clinical and biopharma sectors.
North America NGS Market YOY Growth (%), 2020-2035
Year-over-year growth in the North America NGS market is expected to peak during 2025–2030, averaging 10.5% annually. As the market matures and broadens its base in diagnostics and research, growth rates will gradually normalize post-2030 to an estimated 7% by 2035, maintaining the region's global leadership in sequencing technologies.
North America NGS Market Share by Country/Region, 2025
The United States accounts for the dominant share of the North America NGS market in 2025, propelled by early technology adoption, strong R&D infrastructure, and leadership in precision medicine. Canada and Mexico collectively represent a growing portion, benefiting from expanding healthcare access and investment.
North America NGS Market Share by Company, 2025
Illumina commands the largest share of the North American NGS market in 2025, leveraging its broad NGS platform offerings and strategic partnerships. Thermo Fisher Scientific and Pacific Biosciences are next, each contributing through technological innovation and market expansion, alongside a competitive field of emerging companies.
North America NGS Market Share by Buyer, 2025
Academic and research institutions remain the largest buyers of NGS solutions in North America, leveraging funding for population-scale studies and clinical research. Clinical laboratories and hospitals are fast-growing buyers as diagnostics become more mainstream, with pharmaceutical and biotech companies maintaining steady demand for drug discovery.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 5450 |
| Regions | United States, Canada, Mexico |
| Segments | Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, RNA Sequencing, Methylation Sequencing, Other Types; Diagnostics, Drug Discovery, Biomarker Discovery, Personalized Medicine, Agricultural & Animal Research, Others; Distribution Channels; Technology; Organization Size |
| Players | Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Agilent Technologies, QIAGEN, F. Hoffmann-La Roche, PerkinElmer, Eurofins Scientific, Macrogen, Genomatix, Genapsys, GENEWIZ, Bio-Rad Laboratories |
Key Recent Developments
- June 2024: Illumina launches its latest NovaSeq X Plus system, doubling data output and reducing whole genome sequencing cost per sample.
- July 2024: Thermo Fisher Scientific partners with major North American cancer centers to deploy advanced Ion Torrent Genexus platforms for clinical oncology.
- August 2024: Roche collaborates with multiple US-based personalized medicine labs to expand comprehensive cancer genomic profiling services.
- September 2024: Agilent Technologies introduces new SureSelect NGS panels tailored for rapid agricultural genomics deployments.
- October 2024: QIAGEN unveils QIAseq Multimodal Panels, streamlining biomarker discovery for clinical and research clients in North America.
